Skyhawk news

Browse:

Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression

April 22, 2024
Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D
Ipsen has swooped on a $1.8 billion R&D opportunity, joining with Skyhawk Therapeutics for the chance to option two candidates that could...
Read
1 min read
March 25, 2024
Skyhawk Has Advanced to Multiple Ascending Dose in it’s SKY-0515 Huntington’s Trial
SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform.
Read
2 min read
October 23, 2023
Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small
SKY-0515 is a small molecule RNA splicing modifier developed through the company’s novel SKYSTAR®
Read
3 min read
May 17, 2023
Drugging RNA
Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success.
Read
1 min read
September 7, 2022
Drugging RNA with Pills : Small Molecules for a Big Frontier
Can biotechnology startups turn what were once accidental discoveries into a purposeful way to hit hard-to-reach disease targets?
Read
1 min read